Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy
Journal of Nuclear Medicine · 2025-05 · 66 (5) · 665-672
DOI: 10.2967/jnumed.124.267730 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 27.02.2025. Verfasst von Fabio Turco und 4 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; fabio.turco@eoc.ch. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Prostatic Neoplasms, Antigens, Surface, Glutamate Carboxypeptidase II. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 59 Literaturangaben.
Abstract (Originalsprache)
The treatment landscape of prostate cancer is quite complex because of the many therapeutic options available in different disease settings (hormonal treatments, chemotherapy, poly(adenosine diphosphate ribose) polymerase inhibitors, radiopharmaceutical therapy). Since in most cases we do not have comparative studies between these different agents, the best therapeutic sequence in patients with prostate cancer remains unsolved. In this review, we describe the different systemic therapeutic options available in each disease setting from localized disease to metastatic castration-resistant disease. We also indicate when to use each of these therapeutic options in the therapeutic sequence on the basis of the results of the available studies. A special focus of this review is the place of prostate-specific membrane antigen radiopharmaceutical therapy in the treatment algorithms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; fabio.turco@eoc.ch.
- Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
- Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland.
- Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany.
- Clinic of Nuclear Medicine and Molecular Imaging, Imaging Institute of Southern Switzerland, EOC, Bellinzona, Switzerland; and.
- Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.
Zitieren
APA
Turco, F., Gillessen, S., Herrmann, K., Paone, G., & Omlin, A. (2025). Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy. Journal of Nuclear Medicine, 66(5), 665-672. https://doi.org/10.2967/jnumed.124.267730
Vancouver
Turco F, Gillessen S, Herrmann K, Paone G, Omlin A. Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy. Journal of Nuclear Medicine. 2025;66(5):665-672. doi:10.2967/jnumed.124.267730
BibTeX
@article{Turco2025,
author = {Turco, Fabio and Gillessen, Silke and Herrmann, Ken and Paone, Gaetano and Omlin, Aurelius},
title = {Treatment Landscape of Prostate Cancer in the Era of PSMA Radiopharmaceutical Therapy},
journal = {Journal of Nuclear Medicine},
year = {2025},
volume = {66},
number = {5},
pages = {665--672},
doi = {10.2967/jnumed.124.267730}
}
EUVIMED